{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:54:14Z","timestamp":1760057654919,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to progression despite androgen deprivation therapy (ADT). Current treatments, including androgen receptor-targeted agents, chemotherapy, bone-targeted agents, and PARP inhibitors, extend survival but face challenges, such as resistance, adverse effects, and limited durability. Metastasis-directed therapies (MDTs), such as stereotactic ablative radiotherapy (SABR), show promise in oligometastatic disease, but their role in oligoprogressive mCRPC is unclear. Salvage lymphadenectomy is rarely pursued due to invasiveness and limited data. This is the first report of robotic surgery as an MDT in this setting, demonstrating the potential of salvage robot-assisted video-endoscopic inguinal lymphadenectomy (RAVEIL) to manage oligoprogressive mCRPC and delay systemic progression. Methods: A 47-year-old male with metastatic hormone-sensitive prostate cancer (Gleason 10) underwent ADT, docetaxel chemotherapy, and radical retropubic prostatectomy with super-extended pelvic and retroperitoneal lymphadenectomy. Upon progression to oligoprogressive mCRPC, 68Ga-PSMA PET\/CT detected a single metastatic inguinal lymph node. Salvage RAVEIL was performed using the da Vinci X\u2122 Surgical System, guided by preoperative ultrasound mapping. Results: Histopathology confirmed metastasis in one of the eight excised lymph nodes. The patient achieved undetectable PSA levels and prolonged biochemical progression-free survival. Minor complications (lymphorrhea, cellulitis) resolved without sequelae. No further progression was observed for over 14 months. Conclusions: This case highlights RAVEIL as a viable MDT option for oligoprogressive mCRPC, potentially extending progression-free intervals while minimizing systemic treatment.<\/jats:p>","DOI":"10.3390\/curroncol32020115","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T03:47:06Z","timestamp":1739850426000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-298X","authenticated-orcid":false,"given":"Rafa\u0142 B.","family":"Drobot","sequence":"first","affiliation":[{"name":"Urology Department, Institute of Medical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszy\u0144ski University in Warsaw, Bursztynowa St. 2, 04-479 Warsaw, Poland"},{"name":"Department of Urology and Urological Oncology, Multidisciplinary Hospital in Warsaw-Miedzylesie, Bursztynowa 2 Street, 04-749 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Lipa","sequence":"additional","affiliation":[{"name":"Urology Department, Institute of Medical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszy\u0144ski University in Warsaw, Bursztynowa St. 2, 04-479 Warsaw, Poland"},{"name":"Department of Urology and Urological Oncology, Multidisciplinary Hospital in Warsaw-Miedzylesie, Bursztynowa 2 Street, 04-749 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur A.","family":"Antoniewicz","sequence":"additional","affiliation":[{"name":"Urology Department, Institute of Medical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszy\u0144ski University in Warsaw, Bursztynowa St. 2, 04-479 Warsaw, Poland"},{"name":"Department of Urology and Urological Oncology, Multidisciplinary Hospital in Warsaw-Miedzylesie, Bursztynowa 2 Street, 04-749 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.euf.2018.02.015","article-title":"Standard of Care Versus Metastases-Directed Therapy for PET-Detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-Institutional Case-Control Study","volume":"5","author":"Steuber","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy","volume":"76","author":"Pasquier","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_5","unstructured":"ClinicalTrials.gov (2025, February 09). START-MET: Stereotactic Body Radiotherapy and Androgen Deprivation Therapy for Oligometastatic Prostate Cancer (NCT05209243), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05209243."},{"key":"ref_6","unstructured":"ClinicalTrials.gov (2025, February 09). PRESTO: Prostate-Specific Antigen (PSA) Response Evaluation for Streamlining Trial Optimization (NCT04115007), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04115007."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","article-title":"Robot-assisted PSMA-radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: The first prospective feasibility study","volume":"82","author":"Donswijk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-21-2510","article-title":"Phase II Evaluation of 8Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET\/CT\u2013Identified Oligometastatic Castration-Resistant Prostate Cancer","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1007\/s00259-021-05298-z","article-title":"Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET\/CT in castration-resistant prostate cancer patients","volume":"48","author":"Onal","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","article-title":"Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodeoxyglucose PET\/CT in patients with nonmetastatic prostate cancer with early PSA progression on androgen deprivation therapy: A prospective single-center study","volume":"5","author":"Pan","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.euo.2024.04.003","article-title":"Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: Final results from the prospective, single-arm, phase 2 MEDCARE trial","volume":"7","author":"Rans","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_14","first-page":"1423","article-title":"Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer: A multicentric analysis","volume":"128","author":"Francolini","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2024.42.4_suppl.132","article-title":"ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer","volume":"42","author":"Francolini","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Le Guevelou, J., Cuccia, F., Flippot, R., Ferrera, G., Terlizzi, M., Zilli, T., De Crevoisier, R., Hannoun-Levi, J.M., Supiot, S., and Sargos, P. (Prostate Cancer Prostatic Dis., 2024). The Current Landscape of Stereotactic Body Radiation Therapy for Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Prostatic Dis., in press.","DOI":"10.1038\/s41391-024-00862-8"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101655","DOI":"10.1016\/j.adro.2024.101655","article-title":"Time to Next Systemic Therapy After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer","volume":"9","author":"Eule","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108553","DOI":"10.1016\/j.ejso.2024.108553","article-title":"Comparing the Safety and Effectiveness of Minimally Invasive Surgery and Open Inguinal Lymph Node Dissection in Penile Cancer: A Systematic Review and Meta-Analysis","volume":"50","author":"Ge","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112.e11","DOI":"10.1016\/j.urolonc.2021.11.010","article-title":"Robotic-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) and Video-Endoscopic Inguinal Lymphadenectomy (VEIL) versus Open Inguinal Lymph-Node Dissection (OILND) in Carcinoma of Penis: Comparison of Perioperative Outcomes, Complications and Oncological Outcomes. A Systematic Review and Meta-Analysis","volume":"40","author":"Patel","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.juro.2017.12.061","article-title":"Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis","volume":"199","author":"Singh","year":"2018","journal-title":"J. Urol."},{"key":"ref_21","first-page":"11","article-title":"Robotic Surgery in Comparison to the Open and Laparoscopic Approaches in the Field of Urology: A Systematic Review","volume":"17","author":"Zahid","year":"2023","journal-title":"J. Robot. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Goudarzi, Z., Lotfi, F., Najafpour, Z., Hafezi, A.A., Alizadeh Zakaria, M., and Keshavarz, K. (2024). Cost-Effectiveness and Budget Impact Analysis of Enzalutamide in Comparison to Abiraterone in Treatment of Metastatic Prostate Cancer Resistant to Castration in Iran. BMC Urol., 24.","DOI":"10.1186\/s12894-024-01431-w"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s12325-020-01260-x","article-title":"Economic Outcomes in Patients with Chemotherapy-Na\u00efve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone","volume":"37","author":"Ramaswamy","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.21037\/atm-22-3637","article-title":"Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Patients with Metastatic Castration-Resistant Prostate Cancer in China and United States","volume":"10","author":"Xu","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol29050275","article-title":"The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer\u2014A Systematic Literature Review with Application to the Canadian Context","volume":"29","author":"Yanev","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/iju5.12589","article-title":"A case of repeat oligoprogressive castration-resistant prostate cancer treated with pulmonary metastasectomy","volume":"6","author":"Soma","year":"2023","journal-title":"IJU Case Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s11255-019-02233-y","article-title":"Carbon 11-Choline Positron Emission Tomography\/Computed Tomography and Palliative Local Therapy for Castration-Resistant Prostate Cancer","volume":"51","author":"Nozaki","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bju.16574","article-title":"The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial","volume":"135","author":"Kato","year":"2025","journal-title":"BJU Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/bju.15088","article-title":"Pelvic exenteration surgery in patients with locally advanced castration-na\u00efve and castration-resistant symptomatic prostate cancer","volume":"126","author":"Heidenreich","year":"2020","journal-title":"BJU Int."},{"key":"ref_30","first-page":"106","article-title":"Multicenter study on multidisciplinary committees in advanced prostate cancer","volume":"46","year":"2022","journal-title":"Actas Urol. Esp."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pros.24167","article-title":"Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients","volume":"81","author":"Zhu","year":"2021","journal-title":"Prostate"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hahn, A.W., Aparicio, A., Jadvar, H., and Poon, D.M.C. (Prostate Cancer Prostatic Dis., 2024). MDT Perspective: Innovative Applications of Stereotactic Body Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Prostatic Dis., ahead of print.","DOI":"10.1038\/s41391-024-00922-z"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:36:33Z","timestamp":1760027793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020115"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020115","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}